Chiasma Inc (NASDAQ:CHMA)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - CHMA

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - CHMA

  • Market Cap$243.200m
  • SymbolNASDAQ:CHMA
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS16706W1027

Company Profile

Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA® for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.Chiasma Inc is a biopharmaceutical company which focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases.

Latest CHMA news

Currently there for this company. Visit our news hub for other news .